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ABSTRACT
Introduction: Currently identification, and therefore,
management of patients at risk of osteoporotic fracture in
the UK is suboptimal. As the majority of patients who
fracture have fallen, it follows that people who fall can
usefully be targeted in any programme that aims to
reduce osteoporotic fracture. Targeting vulnerable
patients who are likely to benefit from intervention may
help shift the management of fracture prevention into
primary care, away from emergency departments.
Paramedics who attend to patients who have fallen may
be well placed to assess future fracture risk, using the
Fracture Risk Assessment Tool (FRAX) and communicate
that information directly to general practitioners (GPs).
Methods and analysis: This feasibility study takes the
form of a pragmatic, randomised controlled trial aimed at
exploring and refining issues of study design,
recruitment, retention, sample size and acceptability
preceding a large-scale study with fracture as the end
point. Patients (aged >50) who fall, call an ambulance,
are attended by a study paramedic and give verbal
consent will be asked FRAX and fall questions. Patients
who subsequently formally consent to participation will
be randomised to control (usual care) or intervention
groups. Intervention will constitute transmission of
calculated future fracture risk to the patients’ GP with
suitable, evidence-based recommendations for
investigation or treatment. 3 months after the index fall,
data (proportion of patients in each group undergoing
investigation or starting new treatment, quality of life and
health economic) will be collected and analysed using
descriptive statistics. A nested qualitative study will
explore issues of acceptability and study design with
patients, paramedics and GPs.
Ethics and dissemination: This protocol was
approved by NRES Committee South Central Oxford C in
October 2012. Research Ethics Committee ref.12/SC/
0604. The study findings will be disseminated through
peer-reviewed journals, conference presentations and
local public events. A publication plan and authorship
criteria have been preagreed.
Trial registration number: ISRCTN: 36245726.
INTRODUCTION
Osteoporotic fractures are increasingly fre-
quent, with an incidence over 300 000 annu-
ally in the UK.1 Such fractures are often
painful and disabling.2 Hip fractures are asso-
ciated with greatest disability and may be pre-
dicted by prior fragility fractures at the wrist
or spine.2 Despite this, only a third of
patients who experience such breaks are pre-
scribed treatment to reduce future fracture
risk.1 The identification, and therefore, man-
agement of patients at risk of osteoporotic
fracture in the UK at present is suboptimal.1
Falls occur increasingly frequently with
age. In total, 35% of people aged over 65 fall
each year rising to 50% at age 85.3 4 Many
patients fall repeatedly. 56% of patients
attending an emergency department
reported recurrent falls, and 55% of patients
presenting with an acute fracture had previ-
ously fallen.5 A fall with osteoporosis is par-
ticularly risky. In a study of 2649
postmenopausal women, those with osteopor-
osis were 2.8 times more likely to fracture
than those without, and osteoporotic women
with a history of fall 24.8 times more likely,
even after taking age and body mass index
into account.6 Treatment to reduce fracture
risk in those with osteoporosis is known to be
cost-effective7 8 but there is far less evidence
to suggest benefit in targeting people who
fall for fracture risk assessment.9 A high pro-
portion of people who fall and call an ambu-
lance are not reviewed by their general
practitioner (GP). Only 25% of such patients
visit their general practice within 3 months of
a fall.10
Treatment of patients considered at high
risk of fracture might consist of a
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combination of non-medication (education, physiother-
apy, balance classes) and medication options. Fracture
rates may be reduced by calcium and vitamin D supple-
mentation among older people who live in care
homes.11 Specific treatments such as the bisphospho-
nates (for example, oral alendronate or intravenous
zoledronate) can reduce future fracture rate between
40% and 50%.7
Drug treatment thresholds, based on a combination of
fracture risk, age and gender, have been set in the UK
by the National Osteoporosis Guideline Group
(NOGG).12 Both National Institute for Health and Care
Excellence (NICE) and NOGG recognise that falls play
an important part in fracture risk, but neither include
fall history in their risk-profiling algorithms.
However, NICE has published guidance to help clini-
cians identify patients most at risk of fragility (low
impact or osteoporotic) fracture.13–16 Technology
Appraisal Guidelines (TAG) 160/16113 14 advise the use
of clinical factors (family history of hip fracture, condi-
tions associated with osteoporosis, early menopause,
excessive alcohol consumption) to target dual energy
X-ray absorptiometry (DXA) scans and/or treatment to
postmenopausal women. Healthcare commissioners are
charged with ensuring NICE guidance is implemented
nationally. However the advice is complex (particularly
TAG160) and uptake has been poor.1 NICE guidance
also specifically excludes women taking corticosteroids,
and men.
Assessment of future fracture risk is central to good
management, and the Fracture Risk Assessment Tool
(FRAX) has been developed to enable identification of
individuals most at risk of fragility fracture.17 FRAX is a
validated and freely available algorithm in the form of a
calculator that estimates a 10-year absolute risk of fragil-
ity fracture from patient data inputted online. The
online calculator is clear, easy to use and allows risk cal-
culation in postmenopausal women, patients taking cor-
ticosteroids and men aged 50 years or over.
As the majority of patients who fracture have fallen, it
follows that people who fall can usefully be targeted in
any programme to reduce osteoporotic fracture.
Targeting such a population may allow the identification
of vulnerable patients who are likely to benefit from
intervention, and serve to further shift the burden of
fracture prevention into primary care. As people who
fall are often attended by paramedics,10 involving these
professionals in the assessment of future fracture risk
has the potential to impact on follow-up and manage-
ment. Specifically, if paramedics help to determine a
patient’s 10-year fracture risk at the time of a fall, if that
information is conveyed to their GP, and if the GP acts
on the recommendations, then a higher proportion of
patients may be treated according to the national frac-
ture prevention guidelines.
It is possible that introducing routine FRAX assess-
ment by paramedics of all patients who fall and call an
ambulance could reduce long-term fracture rates. In
order to justify such a service development, evidence of
fracture reduction is required. A large (expensive) trial,
conducted over a number of years would be needed to
address this important question. Before such an under-
taking, it is wise to assess the feasibility of such an
approach, to explore the possibilities and potential pit-
falls of the intervention, to inform the design of a
large-scale randomised trial aimed at reducing fragility
fracture rates over the coming years in those who fall.
AIM
Our future aim is to determine whether FRAX adminis-
tered opportunistically by paramedics to people who fall
improves diagnosis and treatment of patients at high risk
of fracture, leading to a reduced fracture rate. To design
such a trial (in the future), we need to conduct a feasi-
bility study to collect data (quantitative and qualitative)
to inform the effective design of the main (fracture
reduction) trial.
OBJECTIVES
To achieve the aim of the feasibility study we have set
the following objectives:
1. To find out if paramedics are in a position to ask
the necessary questions and gather the right infor-
mation to be able to reliably calculate fracture risk.
2. To determine if the paramedics will collect the
information (and submit it) in a busy service
setting, and if not, what barriers might exist.
3. To determine recruitment, eligibility and consent
rates, and the proportion of participants who con-
tinue to study completion.
4. To establish the proportion of patients who are eli-
gible for treatment to reduce fracture risk according
to the national fracture prevention guidance.
5. To collect demographic (gender, age) data and
information on the relative rate of GP attendance,
referral for investigation (DXA scan) or treatment
(with reference to the NICE/NOGG guidance),
between the intervention and control group.
6. Identify, measure and value resources required to
deliver the intervention.
7. Develop the methods to collect resources used in
the National Health Service (NHS) for the follow-up
period, including retrieving resource-use data from
GP practices and hospitals.
8. Collect the patient-completed resource use question-
naires at follow-up to allow an economic evaluation
from the perspective of the healthcare user in a
future trial.
9. Collect the number of patients completing the
generic quality-of-life Euroqol18 (EQ-5D-5L) ques-
tionnaire at baseline and follow-up.
10. To determine the acceptability of the trial design
and intervention for the patients (and carers where
appropriate), paramedics and GPs.
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Our objectives will contribute to our aim (above) to
design a well-informed, adequately sized, robust, multi-
centre randomised controlled trial (RCT), to determine
whether the intervention has the capacity to increase
the proportion of patients at high risk of fracture pre-
scribed treatment in keeping with existing national
guidelines.
METHODS AND ANALYSIS
Study design
The feasibility study will take the form of a pragmatic,
RCT (allocation ratio 1:1) to explore and refine issues of
study design, recruitment, retention, sample size and
acceptability to inform a future, multicentre, appropri-
ately powered RCT. It will include assessment using
quantitative and qualitative approaches.
The proposed intervention is a service development in
which a patient’s GP is informed about their fall and
their future fracture risk, as assessed at the time of their
fall using FRAX.
In practice, a specialist osteoporosis or falls nurse (or
equivalent) will use the data collected by paramedics to
formulate advice for the GP, however, for the purposes
of this feasibility study, the place of the nurse will be
taken by a member of the research staff (figure 1).
Setting
The study will be carried out by paramedics based at an
urban ambulance station (study site may be obtained by
contacting the corresponding author).
Target population
Men and women aged 50 or over who have fallen and
called an ambulance.
Inclusion and exclusion criteria
We will include:
1. Men and women aged over 50 who fall (inside or
outside their place of residence), call an ambulance
and are attended by study paramedics. Men and
women under the age of 50 who fall are unlikely to
experience a fragility fracture.
We will exclude:
2 Patients who, in the paramedic’s opinion, are medic-
ally unstable and for whom it would not be appropri-
ate to delay treatment to ask study questions (for
example, where the paramedics suspect a cardiac
incident).
3 Patients who have fallen in a public place and, in the
opinion of the treating paramedics should be con-
veyed without delay.
4 Patients who are deemed to lack capacity (according
to the Mental Health Act (2005)) but for whom there
is no available carer or consultee.
5 Patients whose home address is outside the defined
urban and suburban catchment.
6 Patients who are admitted to hospital for 24 h or
more. These patients will need to be excluded by the
researcher prior to consent (pre-existing service
arrangements cover inpatients and our principal
target population is in primary care).
We will continue to monitor patients who fall twice or
more during the study period, but count the first fall as
the index event. Only the first eligible fall will trigger
entry into the study.
Intervention
The intervention will be the calculation of future fracture
risk of patients who fall, and the transmission of clear, tai-
lored advice (based on national guidance) regarding
investigation and treatment, to the patient’s GP.
Control
Usual care. This means participants are free to visit their
GP, or seek further help after their fall, but that we will
not prompt such an action. We will not calculate fracture
risk in these patients.
All patients (intervention and control) will receive a
leaflet about falls phrased in general terms and
approved by patient research partners.
Recruitment and sample size
Paramedics working at the nominated ambulance
station attend about 4200 people who fall, each year.
The Trust employs 100 full time equivalent (FTE) staff.
Each FTE will attend an average 0.8 falls each working
week, or between 1 and 2 fallers per ambulance/week.
If 25% of patients are eligible and consent to inclusion,
it will take 20 paramedics 25 working weeks to recruit 100
participants. Paramedics will seek to collect information
from around 400 eligible patients (figure 2).
Potential for discrimination between control and
intervention groups
There is no prospective data linking DXA-determined
osteoporosis with people who fall. Evidence from heel
scans suggests 42% women (>65 years) who fall have
osteoporosis.19 We might therefore expect about 15–20
patients in the intervention group to be eligible for
treatment.
Paramedic professional development
We will provide professional development sessions to
approximately 20 volunteer paramedics, employed by
SWAFT to take part in this research. The paramedics will
receive overtime payments to attend. The sessions will be
carried out in small groups (4–6), face to face, and facili-
tated by an experienced clinician according to a preagreed
session plan. The paramedics will learn about research,
receive refresher training in the Mental Capacity Act, find
out about the importance of osteoporosis and learn how
to use the FRAX tool. There will be an interactive session
designed to allow the paramedics to try out the study
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paperwork, in particular, asking the FRAX questions of a
volunteer (drawn from the patient participation group).
After the time to ask questions, the paramedic will be
appraised in their use of the study literature.
Study plan
Paramedics will ensure the patient is medically stable
and comfortable. If the patient is eligible (see inclusion
and exclusions 1–4) the paramedic will seek verbal
agreement from the patient to ask FRAX questions relat-
ing to osteoporosis risk and falling, and for a member of
the research team to contact them later about the study.
Paramedics will defer to the patient’s carer or consultee
for verbal agreement if the patient lacks capacity.
The paramedic will use a double-sided sheet to record
the patient’s verbal consent on one side, and the
answers to questions about fracture (FRAX) and fall risk
on the other (see online supplementary appendix 1).
He or she will then return the completed paper sheets
with the (medication) response bag, at the end of shift,
to the ambulance base.
The patient contact sheets will be transmitted securely
to the researcher. The researcher will then check that
potential participants have not been admitted to hos-
pital for 24 h or longer (exclusion 5).
Within 10 working days of the index fall the
researcher will send an information pack (patient infor-
mation (see online supplementary appendix 2), reply
slip, consent form, stamped addressed return envelope)
to the patient. The researcher will also then telephone
the patient to discuss the study. This will provide an
opportunity for the patient to ask any questions they
may have in order for them to provide valid, written
consent. If the patient prefers to consent in person the
researcher will visit the patient.
If the patient declines, we will call the patient to
enquire after the reason(s) they have opted not to take
part. Thereafter, no further contact will be made. A
postal reminder will be sent if we are unable to make
contact by telephone and the patient does not return the
reply slip. Following written consent, patients will be ran-
domly allocated remotely by Bristol Randomised Trials
Collaboration (http://bristol.ac.uk/cobm/research/
brtc.html) to the intervention or control group, by tele-
phone. Enrolment and allocation will be carried out by
the research fellow. Patients in both arms will receive
acknowledgment of their participation in the trial, and a
leaflet containing general information about falls.
A EQ-5D-5L18 questionnaire will also be included. This is
a general measure of a health-related quality-of-life tool
that yields a health status quality-of-life score.
With the participants’ consent, we will write to their
GPs. GPs will be informed of their patient’s participation
in the study, Primary Care Research Network (PCRN)
endorsement of the project, and that funding is available
to cover the additional practice time required. We will
not write to participants’ GPs who have been allocated to
the control arm until 3 months after the index fall.
Figure 1 A summary of study design (FRAX, Fracture Risk Assessment Tool; GP, general practitioner).
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Patients in the intervention arm will have their future
fracture risk calculated using FRAX.17 A clinical member
of the research team will write to the patient’s GP with
clear advice based on NICE Technology Appraisal
Guideline 160 and 161 (Primary and Secondary
Prevention of Osteoporotic Fracture)13 14 for postmeno-
pausal women (not taking corticosteroids), and from
NOGG for postmenopausal women and men.12
Where investigation or treatment for osteoporosis is
recommended we will include supporting
documentation in the pack (for example, a request
form for DXA, patient information about osteoporosis,
treatments and contact numbers for the local National
Osteoporosis Group and advice line).
We will initiate follow-up 3 months after the index fall.
We will telephone patients in the intervention and control
arms to ask questions about their health, investigations and
new treatments. We will also contact the patients’ GPs with
similar enquiries. Patients will be asked to complete the
quality-of-life questionnaire (EQ-5D-5L) for a second time.
Figure 2 Flow chart showing consent, randomisation and follow-up process (FRAX, Fracture Risk Assessment Tool; GP,
general practitioner).
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The researcher will check emergency department data
and hospital-based medical records to confirm reported
hospital attendances, investigations, existing and newly
prescribed or recommended treatments.
Table 1 provides a summary of data collection at study
entry and 3-month follow-up.
We will send a study report to all patients who partici-
pated but we do not intend to send patients allocated to
the control group specific information about their frac-
ture risk.
Outcome measures
The outcome measures for this feasibility study will be:
1. The percentage of FRAX and fall-related data cor-
rectly collected by paramedics and the percentage of
that information translated to clear advice and
received by the correct GP.
2. The eligibility, recruitment and consent rates, and
the proportion of participants who continue to study
completion.
3. The proportion of patients (men and women) who
fall and who are eligible for, but not taking, treat-
ment to reduce fracture risk according to the
national fracture prevention guidance.
4. The number, age, gender and relative rates of GP
attendance, referral for investigation (DXA scan) or
treatment (NICE or NOGG) between the interven-
tion and control groups.
Data management
Data is stored and backed up on NHS password-
protected computers within secured offices. Patient con-
fidentiality will be protected by anonymising the data
and allocating study numbers. Further, specific details of
data management and patient confidentiality can be
obtained from the corresponding author.
Statistical analysis
For this feasibility study percentages will be calculated
with 95% confidence limits using the exact binomial
method. OR of being treated and/or investigated for
falls and osteoporosis will be calculated with 95% CIs to
provide a range of likely effect sizes to inform the full
trial. Demographic data will be tabulated for those
recruited to the study, for those who meet the exclusion
criteria and for those unwilling to take part. Analysis will
be carried out on data collected prior to patient
discontinuation.
Health economics methods and analysis
This study will pilot the methodology to carry out a cost-
effectiveness analysis in the future trial. The future eco-
nomic evaluation will include a cost-consequences study
at 3 months, comparing costs and outcomes for patients
in the short-term, and, if possible, a cost-effectiveness
model to extrapolate costs and health benefits to the
longer term, incorporating the possible effect of the
intervention in fractures averted.
In this study we will assess the feasibility of collecting
the resource-use data by reporting on the percentage of
completed sets of data returned from patients and from
research staff in case report forms. We will value
resources required to deliver the intervention (training
paramedics, administering the FRAX score and liaising
with GPs) using national estimates for health and social
care20 or local sources when appropriate.
Each health status score produced by the EQ-5D-5L
questionnaire will be allocated a preference-based
quality-of-life weight for the UK population at baseline
and 3 months. This allows quality-adjusted life years
(QALYs) to be derived. A QALY weighs survival by the
quality of life of the patient within that period of time.
We will compute a 3-month incremental QALY using the
area under the curve method and then adjust the QALY
gain against baseline utility using linear regression with
robust SEs.21
Qualitative methods
The qualitative study aims to assess the acceptability and
feasibility of the intervention with patients, GPs and
paramedics. Data collection will involve semistructured
interviews with patients (up to 40), GPs (up to 20) and
Table 1 Summary of data collection
Concept Measure Time point(s)
Sociodemographics Baseline and
3 months
Fracture and fall risk FRAX and falls
questionnaire
Baseline and
3 months
Health-related quality of
life (optional)
EQ-5D-5L Baseline and
3 months
Resource use
questionnaire (optional)
Pro forma 3 months
Fall and fracture
treatments
Pro forma 3 months
Hospital visits and
treatments
Pro forma 3 months
Resources required to
train the paramedics
Pro forma At training
sessions
Resources required
administer the FRAX
tool by paramedics to
fallers
Pro forma At ambulance
call home visit
to faller
Resources required to
compute the FRAX
score to intervention
patients and send
letters to GPs
Pro forma Post
ambulance
visit, in back
office
Qualitative data
(patients/GPs/
paramedics*)
Interview 3 months
Qualitative data
(paramedics)
Observation Throughout
recruitment
*paramedic interviews will be carried out anytime throughout
recruitment.
EQ-5D-5L, Euroqol questionnaire; FRAX, Fracture Risk
Assessment Tool; GP, general practitioner.
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paramedics (up to 20) as well as observation of parame-
dics when attending people who have fallen (8). With
informed consent, interviews will be digitally recorded
and transcribed verbatim. The interviewer/observer will
be an experienced qualitative health researcher.
Semistructured interviews with patients will elicit their
views about the study design, including being asked the
FRAX questions by ambulance crew, the recruitment
process, the process of randomisation and its effect on
differential treatment, and the acceptability of complet-
ing questionnaires and accessing their medical records
3 months post follow-up. Interview participants will be
selected purposively to include a range of patients from
intervention and control groups, genders, ages. Family
carers will be included for their views where
appropriate.
GPs who have received the intervention letters, with
details of a patient’s fracture risk and advice about treat-
ment, will be interviewed to elicit their views on the trial
design and the intervention. GPs will be asked about
their current practice in fracture prevention, their opi-
nions about the information received from the study
team, whether and why they chose to follow recommen-
dations and suggestions for improvement to the inter-
vention and study design. GPs will be purposively
selected based on whether they had patients in the inter-
vention arm of the trial.
Selected (and consenting) participating paramedics
will be observed in the course of their daily routine to
help assess the feasibility of the trial processes and
FRAX administration. Triangulating both these methods
and data sets will more accurately assess the acceptability
for paramedics to use FRAX in prehospital care, with
people who have fallen.22 In interviews, paramedics will
be asked about their experience of using FRAX with
their patients who have fallen; their reflections on the
recruitment process; the study training and reminders
provided; the ease, or otherwise, of assessing mental cap-
acity, particularly with regard to research and any other
views on patients who fall.
When observing paramedics, notes will be made
during and after the observation.23 Observations will
take place throughout the recruitment period, examin-
ing the ease of asking the FRAX questions, the quality of
information recorded, whether any barriers exist to car-
rying out the intervention and recruitment, whether any
conversations take place about fracturing and falling pre-
vention, whether any self-care advice is given, if any emo-
tional support is given to patients, and how interagency
relationships with other organisations work. Paramedics
will be purposively sampled based on gender and level
of experience.
The 3 sets of data (patients, GPs and paramedics) will
be analysed separately with the aid of NVivo (V.10). Data
will be inductively coded thematically, producing the-
matic frameworks.24 20% of the transcripts and coding
framework will be double-coded by another experienced
qualitative researcher to ensure dependability and
credibility of findings.25 The thematic coding frame will
be explored and refined24 and findings will be inter-
preted in the light of existing theory and literature. The
qualitative study will provide information about the
acceptability of study processes and the intervention.
DISCUSSION
Although the majority of patients who experience a fra-
gility fracture have done so consequent to a fall, and
there are assessment algorithms that allow us to predict
which patients are most likely to benefit from specific
antiosteoporotic treatment, there is no mechanism
within the NHS that allows for fracture risk assessment
at the time of a fall. Fractures can be painful, disabling
and are expensive to our health system.
This study is designed to collect data to help deter-
mine whether it may be feasible to link falls with fracture
risk at the time a patient asks for help. It addresses the
practicalities of teaching, collecting and delivering the
FRAX information to a patient’s GP and the acceptabil-
ity of the intervention to the patients, paramedics and
GPs. The study will collect data on the number of
patients who fall and are at increased risk of fracture,
and the proportion of those patients who are not
already on treatment.
These data will allow calculation of the size of a subse-
quent RCT to determine whether paramedics, by asses-
sing fracture risk in those who fall, can positively
influence the number of fragility fractures that occur
over a 5-year period.
Dissemination
The final data set will be held by the principal investiga-
tor but will be available on request (with patient identi-
fiers removed to ensure participant confidentiality). The
project outcomes will be relayed to all participants, the
sponsor and funding body. The outcomes will be submit-
ted (with the sponsor and funders approval) to peer-
reviewed journals and for presentation at relevant scien-
tific local and national meetings. A publication plan and
authorship criteria have been preagreed by the research
team.
Study management
The principle investigator will have overall responsibility
for project delivery.
A Project Steering Committee (PSC) will be independ-
ently chaired, will meet twice annually and be consti-
tuted by a majority of independent members who will be
representatives from stakeholder groups (patients,
ambulance service, academic research, general practice
and secondary care). A Patient Advisory Group (PAG)
will be established and meet 6 monthly, prior to the
PSC. The terms of reference for the PSC and PAG are
available from the corresponding author.
A Project Team will meet monthly but also maintains
regular contact outside these times.
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Adverse events
Adverse events will be recorded and the study monitored
and audited in accordance with Trust and Research
Ethics Committee Guidance.
Ethics approval and trial registration
Amendments/modifications to the protocol have and
will only be carried out after agreement from all investi-
gators, the sponsor, funder and with ethical approval.
Although the study was registered with UKCRN on 5
March 2013, there was a delay in registering for an
ISRCTN number, granted 13 March 2014. The trial was
originally registered as qualitative. When it became clear
ISRCTN registration would be appropriate, staffing
issues at National Institute for Health Research (NIHR)
led to a delay in receiving the correct advice.
Protocol amendments
The protocol described here is V.7. From March 2013 a
number of amendments have been approved by the
ethics committee: April 2013 the name of the
Ambulance Trust was changed on the study documenta-
tion, ineligibility criteria were added for patients’ resi-
dent outside the catchment area and the protocol was
revised into Consort format. In October 2013 the option
of face-to face recruitment was added and we were also
granted permission to train clinical desk paramedics at a
city call centre to request verbal consent from patients
who called with a fall (this variation to the protocol was
not actioned). In December 2013, references to ‘ambu-
lance paramedic’ were changed to ‘paramedic’.
Current trial status
Recruitment is planned to complete on 1 July 2014.
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